Biesterfeld and Omya agree to distribute natural and functionalised calcium carbonates

Biesterfeld Spezialchemie is entering into a distribution partnership with Omya, the leading producer of calcium carbonate-based specialties

The collaboration covers the pharmaceutical and nutraceutical sectors. With immediate effect, Biesterfeld will distribute the Swiss manufacturer's innovative excipients and active ingredients Omyapure, Calcipur DC and Omyapharm.

The new agreement applies in Germany and Austria.

Thanks to the new distribution partnership, the product portfolio will be expanded to include innovative pharmaceutical excipients and active ingredients, as well as products for nutraceuticals.

These include Omyapure, a natural calcium carbonate used as a pharmaceutical active ingredient, for example as an acid blocker or for the prevention of osteoporosis.

Calcipur DC is a directly compressible calcium carbonate, used in the nutraceutical sector as an excipient in the manufacture of tablets and characterised by its ease of use.

Omyapharm is an innovative, multifunctional pharmaceutical excipient (coprocessed excipient), used in the manufacture of solid dosage forms (tablets, capsules, granules) in the pharmaceutical industry.

Omyapharm delivers remarkable results in terms of compactability and its ability to absorb liquids. The combination of high hardness together with its fast disintegration is particularly impressive.

Thus, orodispersible tablets (ODTs) made with Omyapharm dissolve in the mouth in just a few seconds. As a result of these outstanding properties, the product was awarded in 2015 with the CPhI Innovation Award as the best Innovation in APIs and Excipients.

"Biesterfeld will be a strong and reliable partner for us. With their proven experience in the pharmaceutical sector and technology-based consulting, Biesterfeld's experts can offer a comprehensive range of services. These are the optimum prerequisites for placing our products on the market in the best possible way and to develop the business together," says Dr Javier Camargo, Global Business Development Manager, Pharmaceuticals and Nutraceuticals, at Omya.

"We are very pleased about the trust our partner Omya has placed in us with these distribution rights," says Dr Andreas Lekebusch, HealthCare Business Manager at Biesterfeld Spezialchemie.

"This partnership allows us to significantly expand our product portfolio with active ingredients and the innovative excipient Omyapharm® and we are very pleased to be able to provide our customers with comprehensive advice and support in the development of solid dosage forms."

Companies